The Development of Malignant Melanoma Concurrent to Encorafenib and Cetuximab Therapy for Gastrointestinal Cancer With Neuroendocrine Features
{{output}}
BRAF inhibitors, among other targeted therapies, have transformed the treatment of many cancers in recent years. While cutaneous malignancies are a known adverse effect of BRAF inhibitors, the following case description highlights the importance of regularly m... ...
